Section Arrow
CCCC.NASDAQ
- C4 Therapeutics
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Last
 1.84
-0.01 (-0.54%)
Day High 
1.9102 
Prev. Close
1.85 
1-M High
2.805 
Volume 
754.90K 
Bid
1.84
Ask
1.85
Day Low
1.8 
Open
1.88 
1-M Low
1.79 
Market Cap 
131.33M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.09 
20-SMA 2.23 
50-SMA 2.94 
52-W High 8.29 
52-W Low 1.79 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.52/-1.33
Enterprise Value
191.31M
Balance Sheet
Book Value Per Share
3.04
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
35.58M
Operating Revenue Per Share
0.29
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harnessthe body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.